Imuger (Azathioprine)

Azathioprine is a pro‑drug that is converted inside cells to 6‑mercaptopurine, a purine analog. This metabolite blocks the synthesis of DNA and RNA, which limits the proliferation of activated T‑ and B‑lymphocytes. By reducing the number of these immune cells, azathioprine dampens the overall immune response.

The specific dose of Imuger is individualized by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and response to therapy. Dosage adjustments are made during treatment to achieve the desired immunosuppressive effect while minimizing adverse reactions.

Azathioprine crosses the placenta and is excreted in breast milk, so its safety in pregnancy and lactation is not fully established. Physicians weigh potential benefits against risks, and women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives or necessary precautions with their healthcare provider.

To place an order, visit the Imuger product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, azathioprine offers a different mechanism—purine synthesis inhibition—resulting in a distinct side‑effect profile. It is often used when patients cannot tolerate calcineurin inhibitors or as part of combination therapy to achieve synergistic immunosuppression.

Imuger should be stored at room temperature, below 25 °C. Keep the tablets in the original blister or bottle, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Imuger is taken orally, usually with food to reduce gastrointestinal irritation. The tablet is swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician and should not alter the timing or frequency without medical advice.

The most serious risks include severe bone‑marrow suppression leading to infections, hepatotoxicity that can progress to liver failure, pancreatitis, and a long‑term increased risk of certain cancers such as lymphomas and skin malignancies. Regular laboratory monitoring is essential to detect these complications early.

Imuger is contraindicated in patients with known hypersensitivity to azathioprine or its metabolites, those with active severe infections, and individuals with significant bone‑marrow failure or severe hepatic impairment. It should also be used with caution in pregnant or breastfeeding women and in patients with renal dysfunction, after appropriate clinical assessment.